Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Tomoaki SonodaYukihiro UmedaYoshiki DemuraToshihiko TadaKoki NakashimaMasaki AnzaiMakiko YamaguchiAkikazu ShimadaMasahiro OhiChisato HonjoYuko WasedaMasaya AkaiTamotsu Ishizuka

Published in: Cancer medicine (2023)

Nab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
clinical trial
combination therapy
open label
double blind
cross sectional
tyrosine kinase
phase ii
mesenchymal stem cells
stem cells